Japan

Epsilon Molecular Engineering

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

Virtual Innovation Day

Participation Not Confirmed

Update your events

Series A Financing of 570 Million Yen Procured by Epsilon Molecular Engineering

Lead Product(s): VHH antibody

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Mitsubishi UFJ Capital

Deal Size: $5.4 million Upfront Cash: Undisclosed

Deal Type: Series A Financing December 23, 2020

Details:

With these investments, Epsilon Molecular Engineering plans to further promote its next-generation biotechnology-based drug discovery research and development focusing on heavy chain single domain antibodies, VHH antibody.

Kao Corporation

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

Virtual Innovation Day

Participation Not Confirmed

Update your events

GHIT Fund Announces New Investments in a Lead Optimization trial for Soil-transmitted helminths Drug

Lead Product(s): Undisclosed

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: GHIT Fund

Deal Size: $0.8 million Upfront Cash: Undisclosed

Deal Type: Funding September 29, 2020

Details:

Funds will be used for Cry5B optimization for Trichuris - whipworm which is beign conducted by Kao Corporation, PATH, University of Massachusetts Medical School.